Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Funda Meric-Bernstam

Showing results (461-470 of 643) with videos related to

Pageof 65
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2018
Precision Oncology Decision Support: Current Approaches and Strategies for the FutureKatherine C Kurnit, Ecaterina E Ileana Dumbrava, Beate Litzenburger, et al.
Cancer Cell|March 14, 2018
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination DeficiencyChaoyang Sun, Jun Yin, Yong Fang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2024
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 StudyAditya Bardia, Ian E Krop, Takahiro Kogawa, et al.
Investigational New Drugs|September 25, 2021
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Oncotarget|April 21, 2017
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomasRoman Groisberg, David S Hong, Vijaykumar Holla, et al.
The Lancet. Oncology|August 2, 2021
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket studyMilind Javle, Mitesh J Borad, Nilofer S Azad, et al.
Journal of Immunotherapy and Precision Oncology|February 8, 2024
Limited Independent Follow-Up with Germline Testing of Variants Detected in <i>BRCA1</i> and <i>BRCA2</i> by Tumor-Only SequencingCarol J Nowlen, Molly Daniels, Burak Uzunparmak, et al.
Journal for Immunotherapy of Cancer|September 20, 2019
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinomaMouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE<sub>2</sub>-receptor E-type 4 (EP4), in patients with advanced cancersDavid S Hong, Aparna Parikh, Geoffrey I Shapiro, et al.
NPJ Precision Oncology|July 31, 2024
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterationsSarina A Piha-Paul, Chieh Tseng, Cheuk Hong Leung, et al.
Pageof 65

Showing results (461-470 of 643) with videos related to

Sort By:
Pageof 65
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2018
Precision Oncology Decision Support: Current Approaches and Strategies for the FutureKatherine C Kurnit, Ecaterina E Ileana Dumbrava, Beate Litzenburger, et al.
Cancer Cell|March 14, 2018
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination DeficiencyChaoyang Sun, Jun Yin, Yong Fang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2024
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 StudyAditya Bardia, Ian E Krop, Takahiro Kogawa, et al.
Investigational New Drugs|September 25, 2021
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Oncotarget|April 21, 2017
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomasRoman Groisberg, David S Hong, Vijaykumar Holla, et al.
The Lancet. Oncology|August 2, 2021
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket studyMilind Javle, Mitesh J Borad, Nilofer S Azad, et al.
Journal of Immunotherapy and Precision Oncology|February 8, 2024
Limited Independent Follow-Up with Germline Testing of Variants Detected in <i>BRCA1</i> and <i>BRCA2</i> by Tumor-Only SequencingCarol J Nowlen, Molly Daniels, Burak Uzunparmak, et al.
Journal for Immunotherapy of Cancer|September 20, 2019
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinomaMouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE<sub>2</sub>-receptor E-type 4 (EP4), in patients with advanced cancersDavid S Hong, Aparna Parikh, Geoffrey I Shapiro, et al.
NPJ Precision Oncology|July 31, 2024
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterationsSarina A Piha-Paul, Chieh Tseng, Cheuk Hong Leung, et al.
Pageof 65